Clinicopathological analysis of expression of immune checkpoint molecules in patient with resected lung cancer

2016 Fiscal Year Final Research Report

• Project/Area Number: 26462144
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory surgery
• Research Institution: National Hospital Organization, Kyushu Cancer Center
• Principal Investigator: Mitsuhiro Takenoyama 独立行政法人国立病院機構(九州がんセンター臨床研究センター), その他部局等, 呼吸器腫瘍科部長 (10309966)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 免疫チェックポイント / 呼吸器悪性腫瘍 / PD-1 / driver mutation

Outline of Final Research Achievements

A new immunological therapy using by immune checkpoint inhibitors has developed as a standard therapy against advanced non-small cell lung cancer recently. In this study, to elucidate the clinicopathological significance of PD-L1 expression in lung cancer tissues, its expression was analyzed together with oncogenic drivers such asn EGFR and EML4-ALK in the resected specimens from patients with p-stage I adenocarcinoma. Higher expression of PD-L1 was found in 32% out of 228 patients. Low expression of PD-L1 is a poor prognostic marker in patients with EGFR wild type, and is an independent poor prognostic marker in patients with stage IB.

Free Research Field

呼吸器外科、胸部外科